person · Reporting owner

Kong Garheng

Disclosed activity across 10 companies

Tapewire entity: 40892
SEC CIK: 0001435183

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALIMERA SCIENCES INCALIM · Entity 11664	Director	January 04, 2023	January 06, 2023
American Oncology Network, Inc.AONC · Entity 88884	10% owner	October 30, 2023	November 09, 2023
LABCORP HOLDINGS INC.LH · Entity 1277	Director	February 11, 2026	February 13, 2026
MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249	Director	June 12, 2018	June 14, 2018
Ocugen, Inc.HSGX · Entity 5550	Director	June 15, 2018	June 19, 2018
Strongbridge Biopharma plcSBBP · Entity 131608	Director	October 05, 2021	October 06, 2021
Venus Concept Inc.VERO · Entity 55304	Director	March 24, 2023	March 28, 2023
Xeris Biopharma Holdings, Inc.XERS · Entity 4670	Director	June 04, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALIMERA SCIENCES INC

Report date January 04, 2023 · Filed January 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-01-03	Direct	6,000	Reported balance After 2023-01-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-04 · Grant · Acquired 6,000 · Balance 6,000 F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date.

American Oncology Network, Inc.

Report date October 30, 2023 · Filed November 09, 2023

Jointly reported with HealthQuest Tactical Opportunities Fund, L.P., HealthQuest TOF Management, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.00	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-10-30 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Each share of the Series A Preferred Stock is convertible into shares of Class A Common Stock of the Issuer at any time, at the Reporting Person's election. The number of shares of the Issuer's Class A Common Stock received upon conversion of a share of Series A Preferred Stock equals the quotient of (A) the sum of (i) the original issue price of $10.00, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after September 20, 2023, and (ii) any accrued and unpaid dividends on such share, divided by (B) an initial conversion price of $10.00, which is subject to certain anti-dilution adjustments. The Series A Preferred Stock is perpetual and therefore has no expiration date. F2: The shares are held directly by HealthQuest Tactical Opportunities Fund, L.P. ("HealthQuest Tactical Opportunities"). HealthQuest TOF Management, L.L.C. ("HealthQuest TOF Management") is HealthQuest Tactical Opportunities' general partner, and Dr. Garheng Kong is HealthQuest TOF Management's managing member. HealthQuest TOF Management and Dr. Kong may be deemed to have sole voting and dispositive power over the shares held by HealthQuest Tactical Opportunities. HealthQuest TOF Management and Dr. Kong disclaim beneficial ownership of all shares of common stock owned by HealthQuest Tactical Opportunities except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Series A Preferred Stock is convertible into shares of Class A Common Stock of the Issuer at any time, at the Reporting Person's election. The number of shares of the Issuer's Class A Common Stock received upon conversion of a share of Series A Preferred Stock equals the quotient of (A) the sum of (i) the original issue price of $10.00, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after September 20, 2023, and (ii) any accrued and unpaid dividends on such share, divided by (B) an initial conversion price of $10.00, which is subject to certain anti-dilution adjustments. The Series A Preferred Stock is perpetual and therefore has no expiration date.

F2: The shares are held directly by HealthQuest Tactical Opportunities Fund, L.P. ("HealthQuest Tactical Opportunities"). HealthQuest TOF Management, L.L.C. ("HealthQuest TOF Management") is HealthQuest Tactical Opportunities' general partner, and Dr. Garheng Kong is HealthQuest TOF Management's managing member. HealthQuest TOF Management and Dr. Kong may be deemed to have sole voting and dispositive power over the shares held by HealthQuest Tactical Opportunities. HealthQuest TOF Management and Dr. Kong disclaim beneficial ownership of all shares of common stock owned by HealthQuest Tactical Opportunities except to the extent of any pecuniary interest therein.

LABCORP HOLDINGS INC.

Report date February 11, 2026 · Filed February 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,739	Reported balance After 2026-02-11 transaction · row 1 1 source row Row 1 · 2026-02-11 · Exercise / conversion · Acquired 897 · Balance 13,739 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	773	Reported balance After 2026-02-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-11 · Exercise / conversion · Disposed 897 · Balance 773 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2: The Restricted Stock Units vested fully on February 11, 2026. F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2: The Restricted Stock Units vested fully on February 11, 2026.

F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

MELINTA THERAPEUTICS, INC. /NEW/

Report date June 12, 2018 · Filed June 14, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.45 · Expires 2028-04-20	Direct	25,000	Reported balance After 2018-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-12 · Grant · Acquired 25,000 · Balance 25,000 F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.45 · Expires 2028-04-20	Direct	9,100	Reported balance After 2018-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-12 · Grant · Acquired 9,100 · Balance 9,100 F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.

F2: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.

Ocugen, Inc.

Report date June 15, 2018 · Filed June 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14	Direct	25,000	Reported balance After 2018-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.

Strongbridge Biopharma plc

Report date October 05, 2021 · Filed October 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2021-10-05 transaction · row 1 1 source row Row 1 · 2021-10-05 · Disposition to issuer · Disposed 63,993 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-05 · Disposition to issuer · Disposed 154,385 · Balance 0 F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

Filing footnotes · ownership attribution and instrument terms

F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

Venus Concept Inc.

Report date March 24, 2023 · Filed March 28, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2033-03-24	Direct	75,000	Reported balance After 2023-03-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-24 · Grant · Acquired 75,000 · Balance 75,000 F1: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date.

Xeris Biopharma Holdings, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	238,337	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 24,193 · Balance 238,337 F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2036-06-04	Direct	32,996	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 32,996 · Balance 32,996 F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 26, 2019

Section 16 reporting ended · disclosed 2019-11-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2019-11-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-21 · Disposition to issuer · Disposed 1,437,096 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08	Direct	Reported balance After 2019-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein.

F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.

F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

CASTLE BIOSCIENCES INC

Report date May 12, 2020 · Filed May 19, 2020 · Amendment

Jointly reported with Sofinnova HealthQuest Partners, L.P., HealthQuest Venture Management, L.L.C.

Section 16 reporting ended · disclosed 2020-05-19. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,433,577	Last balance in matching sequence After 2020-05-12 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-05-12 · Sale · Disposed 50,000 · Balance 1,633,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F2: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $33.034 to a high of $33.04, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein. Row 2 · 2020-05-12 · Sale · Disposed 100,000 · Balance 1,533,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F4: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $34.0861 to a high of $34.6399, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein. Row 3 · 2020-05-12 · Sale · Disposed 100,000 · Balance 1,433,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F5: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $35.175 to a high of $35.665, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019.

F2: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $33.034 to a high of $33.04, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein.

F4: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $34.0861 to a high of $34.6399, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

F5: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $35.175 to a high of $35.665, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 19, 2019 Filed Feb 20, 2019 00:12 UTC	AVEDRO INC AVDR · Entity 153528	ConversionCommon Stock	561,673	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-011333 · doc4.xml · nonDerivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 758,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein. Read SEC document
February 19, 2019 Filed Feb 20, 2019 00:12 UTC	AVEDRO INC AVDR · Entity 153528	ConversionCommon Stock	87,663	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-011333 · doc4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 197,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein. Read SEC document
February 12, 2019 Filed Feb 14, 2019 21:27 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	1,227	$0.00	$0.00	Disclosure SEC source: 0001127602-19-006004 · form4.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 12, 2019 Filed Feb 14, 2019 21:27 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	1,038	$0.00	$0.00	Disclosure SEC source: 0001127602-19-006004 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. Read SEC document
February 12, 2019 Filed Feb 14, 2019 21:27 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	1,038	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-19-006004 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
June 19, 2018 Filed Jun 20, 2018 20:03 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $0.86	$0.00	Disclosure SEC source: 0001267602-18-000077 · wf-form4_152952495640856.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: Exercisable in equal monthly installments over 12 months starting one month after the grant date, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document
June 15, 2018 Filed Jun 19, 2018 20:41 UTC	Ocugen, Inc. HSGX · Entity 5550	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.97	$0.00	Disclosure SEC source: 0000899243-18-017188 · doc4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. Read SEC document
June 12, 2018 Filed Jun 14, 2018 16:53 UTC	MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249	GrantStock Option (right to buy) · Derivative	9,100	$0.00 Strike: $7.45	$0.00	Disclosure SEC source: 0000899243-18-016631 · doc4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. Read SEC document
June 12, 2018 Filed Jun 14, 2018 16:53 UTC	MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $7.45	$0.00	Disclosure SEC source: 0000899243-18-016631 · doc4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. Read SEC document
May 15, 2018 Filed May 17, 2018 12:40 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantStock Options (Right to Buy) · Derivative	40,000	$0.00 Strike: $7.75	$0.00	Disclosure SEC source: 0001179110-18-006950 · edgar.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-15 Read SEC document
February 12, 2018 Filed Feb 14, 2018 14:08 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	1,038	$0.00	$0.00	Disclosure SEC source: 0001127602-18-005642 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 07, 2018 Filed Feb 9, 2018 20:50 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	1,263	$0.00	$0.00	Disclosure SEC source: 0001127602-18-004892 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2018. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2018. Read SEC document
February 07, 2018 Filed Feb 9, 2018 20:50 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	1,263	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-004892 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
June 22, 2017 Filed Jun 23, 2017 20:32 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001267602-17-000047 · wf-form4_149824993555600.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: Exercisable in equal monthly installments over 12 months starting one month after the grant date, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document
June 13, 2017 Filed Jun 14, 2017 21:00 UTC	Ocugen, Inc. HSGX · Entity 5550	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0000899243-17-016390 · doc4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017. Read SEC document
February 09, 2017 Filed Feb 13, 2017 18:49 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	1,560	$0.00	$0.00	Disclosure SEC source: 0001127602-17-005283 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263 Underlying: Common Stock · 1,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock units vested fully on February 9, 2017. F2 · derivative.expiration_date: The Restricted Stock units vested fully on February 9, 2017. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 09, 2017 Filed Feb 13, 2017 18:49 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	1,560	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-17-005283 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
February 07, 2017 Filed Feb 9, 2017 19:25 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	1,263	$0.00	$0.00	Disclosure SEC source: 0001127602-17-004721 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
January 03, 2017 Filed Jan 5, 2017 21:54 UTC	MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001209191-17-002484 · doc4.xml · derivative · entry 8 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-01-02 F7 · derivative.exercise_date: The option vests on the following schedule: 1/12th of the shares vest monthly at the end of each month over 12 months, beginning after 01/01/2017. Read SEC document
December 16, 2016 Filed Dec 19, 2016 22:04 UTC	Ocugen, Inc. HSGX · Entity 5550	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.58	$0.00	Disclosure SEC source: 0000899243-16-035944 · doc4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.